Announcements Trials
Browse Landscape

Phase

Phase 1 5

Status

Completed 77Terminated 23Active not recruiting 9Recruiting 7Withdrawn 5Unknown 3Not yet recruiting 3No longer available 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Other hematologic neoplasm 5Lymphoid 4Myeloid 1

Conditions

Leukemia, Myeloid, Acute 15Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Leukemia, Lymphocytic, Chronic, B-Cell 7Myelodysplastic Syndromes 6Hematologic Neoplasms 6Multiple Myeloma 5Leukemia 5Burkitt Lymphoma 5Lymphoma, Non-Hodgkin 4Lymphoma, Follicular 4Lymphoma 4Recurrence 3Melanoma 3Lymphoma, Mantle-Cell 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Leukemia, Biphenotypic, Acute 3Breast Neoplasms 3Stomach Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma, B-Cell 2Leukemia, Prolymphocytic 2Hematologic Diseases 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2

Interventions

Cyclophosphamide 10fludarabine phosphate 9Rituximab 9Cytarabine 9Peripheral Blood Stem Cell Transplantation 8Methotrexate 8Filgrastim 6Cyclosporine 6fludarabine 5Radiotherapy 5Busulfan 5Tacrolimus 4Mycophenolic Acid 4Idarubicin 4Granulocyte Colony-Stimulating Factor 4Bendamustine Hydrochloride 4venetoclax 3duvelisib 3Whole-Body Irradiation 3Sirolimus 3Melphalan 3Antilymphocyte Serum 3Prednisone 2N(alpha)-(4-amino-4-deoxypteroyl)-N(delta)-hemiphthaloyl-L-ornithine 2Mitoxantrone 2Lenalidomide 2Interferon-alpha 2Drug Therapy 2Clofarabine 2Arsenic Trioxide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Withdrawn × Leukemia × fludarabine × Clear all
NCT05170828 2026-02-24

Cryopreserved MMUD BM With PTCy for Hematologic Malignancies

Ossium Health, Inc.

Phase 1 Withdrawn
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT02274506 2020-01-22

Infusion of Allogeneic, 3rd Party CD19-specific T Cells

M.D. Anderson Cancer Center

Phase 1 Withdrawn
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02194374 2017-06-12

Autologous ROR1R-CAR-T Cells for Chronic Lymphocytic Leukemia (CLL)

M.D. Anderson Cancer Center

Phase 1 Withdrawn
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01478074 2014-01-03

ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia

Altor BioScience

Phase 1 Withdrawn
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

NCT00972101 2012-10-11

Infusion of Expanded Cord Blood T Cells

M.D. Anderson Cancer Center

Phase 1 Withdrawn
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡